59.19
price down icon3.05%   -1.86
after-market Handel nachbörslich: 59.30 0.11 +0.19%
loading
Schlusskurs vom Vortag:
$61.05
Offen:
$61.21
24-Stunden-Volumen:
10.63M
Relative Volume:
0.96
Marktkapitalisierung:
$120.11B
Einnahmen:
$48.30B
Nettoeinkommen (Verlust:
$-8.95B
KGV:
-13.39
EPS:
-4.42
Netto-Cashflow:
$13.94B
1W Leistung:
-1.19%
1M Leistung:
+1.68%
6M Leistung:
+18.50%
1J Leistung:
+13.28%
1-Tages-Spanne:
Value
$59.18
$61.49
1-Wochen-Bereich:
Value
$59.18
$61.49
52-Wochen-Spanne:
Value
$39.35
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Firmenname
Bristol Myers Squibb Co
Name
Telefon
(609) 252-4621
Name
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Mitarbeiter
34,100
Name
Twitter
@BMSNEWS
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BMY's Discussions on Twitter

Vergleichen Sie BMY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
59.19 120.11B 48.30B -8.95B 13.94B -4.42
Drug Manufacturers - General icon
LLY
Lilly Eli Co
852.35 765.56B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
201.34 355.44B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
161.02 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
73.60 334.39B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.87 235.20B 64.17B 17.12B 18.10B 6.73

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-16 Hochstufung Jefferies Hold → Buy
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-13 Hochstufung Daiwa Securities Neutral → Outperform
2024-11-12 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-25 Herabstufung Citigroup Buy → Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-07-29 Herabstufung Barclays Overweight → Equal Weight
2024-03-11 Herabstufung Societe Generale Buy → Hold
2024-02-06 Herabstufung Redburn Atlantic Buy → Neutral
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-15 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-11-02 Herabstufung Daiwa Securities Outperform → Neutral
2023-10-27 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-10-27 Hochstufung HSBC Securities Reduce → Hold
2023-10-27 Herabstufung William Blair Outperform → Mkt Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-07-14 Eingeleitet HSBC Securities Reduce
2023-07-10 Eingeleitet SVB Securities Market Perform
2023-06-28 Eingeleitet Daiwa Securities Outperform
2023-03-06 Eingeleitet Jefferies Hold
2023-01-17 Eingeleitet Cantor Fitzgerald Overweight
2022-11-18 Eingeleitet Credit Suisse Neutral
2022-10-10 Herabstufung Guggenheim Buy → Neutral
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-06-03 Herabstufung Raymond James Outperform → Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Underweight
2021-12-17 Eingeleitet Goldman Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-11-01 Herabstufung Argus Buy → Hold
2021-07-27 Fortgesetzt Truist Buy
2021-04-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-04-13 Hochstufung Truist Hold → Buy
2020-11-16 Hochstufung Societe Generale Hold → Buy
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-11-06 Herabstufung Gabelli & Co Buy → Hold
2020-10-19 Hochstufung Guggenheim Neutral → Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-07-28 Eingeleitet Raymond James Outperform
2020-04-02 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-01-06 Fortgesetzt Citigroup Buy
2019-12-13 Hochstufung Argus Hold → Buy
2019-11-22 Fortgesetzt Morgan Stanley Equal-Weight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-08-14 Hochstufung Atlantic Equities Neutral → Overweight
2019-05-28 Eingeleitet Goldman Buy
2019-05-20 Herabstufung Argus Buy → Hold
2019-05-03 Hochstufung Barclays Equal Weight → Overweight
2019-05-03 Fortgesetzt JP Morgan Overweight
2019-01-15 Hochstufung Societe Generale Sell → Buy
2018-10-22 Herabstufung Citigroup Buy → Neutral
Alle ansehen

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

pulisher
Mar 25, 2025

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 25, 2025
pulisher
Mar 25, 2025

Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma

Mar 25, 2025
pulisher
Mar 24, 2025

Bristol-Myers Squibb’s SWOT analysis: stock faces legacy challenges amid growth potential - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Is Bristol-Myers Squibb (BMY) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey

Mar 24, 2025
pulisher
Mar 24, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Mar 24, 2025
pulisher
Mar 22, 2025

Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires? - Insider Monkey

Mar 22, 2025
pulisher
Mar 21, 2025

Bristol-Myers Squibb Company (BMY): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey

Mar 21, 2025
pulisher
Mar 21, 2025

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (NYSE:MRK) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace

Mar 21, 2025
pulisher
Mar 20, 2025

Is Bristol-Myers Squibb Company (BMY) The Best Undervalued Stock to Buy According to Billionaires? - Insider Monkey

Mar 20, 2025
pulisher
Mar 20, 2025

Bristol Myers Squibb Names GM for Saudi Arabia and Gulf Countries - Contract Pharma

Mar 20, 2025
pulisher
Mar 20, 2025

Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries - The Malaysian Reserve

Mar 20, 2025
pulisher
Mar 20, 2025

Our impact - Bristol Myers Squibb

Mar 20, 2025
pulisher
Mar 19, 2025

Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In? - Insider Monkey

Mar 19, 2025
pulisher
Mar 18, 2025

Bristol-Myers Squibb: Why I'm Still Bullish (NYSE:BMY) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 17, 2025

7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK

Mar 17, 2025
pulisher
Mar 17, 2025

EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy - Yahoo Finance

Mar 17, 2025
pulisher
Mar 16, 2025

StockWatch: Will BMS–2seventy Deal Prove a Win-Win? - Genetic Engineering & Biotechnology News

Mar 16, 2025
pulisher
Mar 15, 2025

Why Bristol-Myers Squibb Company (BMY) Went Down On Thursday? - Insider Monkey

Mar 15, 2025
pulisher
Mar 15, 2025

Why Bristol-Myers Squibb Company (BMY) Went Down On Friday? - Yahoo Finance

Mar 15, 2025
pulisher
Mar 14, 2025

Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Bristol Myers Squibb’s Breyanzi gets EU nod for lymphoma treatment - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Bristol Myers Squibb Receives Approval From The European Commission To Expand Use Of Car T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Bristol Myers Squibb to acquire 2seventy bio for USD 286 million - Medical Dialogues

Mar 14, 2025
pulisher
Mar 13, 2025

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma

Mar 13, 2025
pulisher
Mar 13, 2025

Bristol Myers Squibb Sets Critical Q1 Earnings Date: What Investors Should Mark on Their Calendar - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

William Blair Issues Optimistic Estimate for BMY Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Bristol-Myers Squibb at Leerink Global Healthcare Conference: Pipeline Progress and Strategic Insights - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

BMS $286m partner buy secures Abecma and closes chapter on bluebird - BioXconomy

Mar 12, 2025
pulisher
Mar 12, 2025

Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance

Mar 12, 2025
pulisher
Mar 11, 2025

11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

BMS to acquire longtime cell therapy partner 2seventy bio for $286m - Pharmaceutical Technology

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers Squibb (BMY) Shares Cross 4% Yield Mark - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers Squibb Acquires 2seventy bio for $286 Million - Lawyer Monthly Magazine

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc. for approximately $280 million. - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc.. -March 10, 2025 - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Eaton's Bold Acquisition Moves Into Data Centers - Finimize

Mar 11, 2025
pulisher
Mar 11, 2025

2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters

Mar 11, 2025
pulisher
Mar 11, 2025

In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - FiercePharma

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Bristol Myers Squibb's Bold Move: Acquiring 2seventy Bio - Finimize

Mar 11, 2025

Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$107.89
price up icon 1.08%
drug_manufacturers_general SNY
$55.45
price down icon 0.86%
drug_manufacturers_general PFE
$25.55
price down icon 2.26%
$306.86
price down icon 2.39%
drug_manufacturers_general NVS
$110.38
price down icon 0.64%
drug_manufacturers_general MRK
$87.87
price down icon 4.81%
Kapitalisierung:     |  Volumen (24h):